115 related articles for article (PubMed ID: 33513373)
1. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P; Hunter AM; Mora E; Geissler K; Dimou M; Jimenez Lorenzo MJ; Melchardt T; Egle A; Viniou AN; Patel BJ; Arnan M; Valent P; Roubakis C; Bernal Del Castillo T; Galanopoulos A; Calabuig Muñoz M; Bonadies N; Medina de Almeida A; Cermak J; Jerez A; Montoro MJ; Cortés A; Avendaño Pita A; Lopez Andrade B; Hellstroem-Lindberg E; Germing U; Sekeres MA; List AF; Symeonidis A; Sanz GF; Larcher-Senn J; Greil R
Lancet Haematol; 2021 Feb; 8(2):e135-e148. PubMed ID: 33513373
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia].
Li X; Wang Y; Guo YJ; Niu ZY; Ma L; Zhou XQ; Zhang JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):257-261. PubMed ID: 38387931
[TBL] [Abstract][Full Text] [Related]
3. CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study.
Peterlin P; Le Bris Y; Turlure P; Chevallier P; Ménard A; Gourin MP; Dumas PY; Thepot S; Berceanu A; Park S; Hospital MA; Cluzeau T; Bouzy S; Torregrosa-Diaz JM; Drevon L; Sapena R; Chermat F; Ades L; Dimicoli-Salazar S; Chevret S; Béné MC; Fenaux P
Lancet Haematol; 2023 Jul; 10(7):e521-e529. PubMed ID: 37245522
[TBL] [Abstract][Full Text] [Related]
4. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Bataller A; Montalban-Bravo G; Bazinet A; Alvarado Y; Chien K; Venugopal S; Ishizawa J; Hammond D; Swaminathan M; Sasaki K; Issa GC; Short NJ; Masarova L; Daver NG; Kadia TM; Colla S; Qiao W; Huang X; Kanagal-Shamanna R; Hendrickson S; Ravandi F; Jabbour E; Kantarjian H; Garcia-Manero G
Lancet Haematol; 2024 Mar; 11(3):e186-e195. PubMed ID: 38316133
[TBL] [Abstract][Full Text] [Related]
5. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G; McCloskey J; Griffiths EA; Yee KWL; Zeidan AM; Al-Kali A; Deeg HJ; Patel PA; Sabloff M; Keating MM; Zhu N; Gabrail NY; Fazal S; Maly J; Odenike O; Kantarjian H; DeZern AE; O'Connell CL; Roboz GJ; Busque L; Buckstein R; Amin H; Randhawa J; Leber B; Shastri A; Dao KH; Oganesian A; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2024 Jan; 11(1):e15-e26. PubMed ID: 38135371
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
Mosquera Orgueira A; Perez Encinas MM; Diaz Varela N; Wang YH; Mora E; Diaz-Beya M; Montoro MJ; Pomares Marin H; Ramos Ortega F; Tormo M; Jerez A; Nomdedeu J; de Miguel Sanchez C; Arenillas L; Carcel P; Cedena Romero MT; Xicoy Cirici B; Rivero Arango E; Del Orbe Barreto RA; Benlloch L; Lin CC; Tien HF; Pérez Míguez C; Crucitti D; Díez Campelo M; Valcárcel D
Br J Haematol; 2024 Apr; 204(4):1529-1535. PubMed ID: 38411250
[TBL] [Abstract][Full Text] [Related]
8. Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Montalban-Bravo G; Jabbour E; Borthakur G; Kadia T; Ravandi F; Chien K; Pemmaraju N; Hammond D; Dong XQ; Huang X; Schneider H; John R; Kanagal-Shamana R; Loghavi S; Kantarjian H; Garcia-Manero G
Br J Haematol; 2024 Mar; 204(3):898-909. PubMed ID: 37946611
[TBL] [Abstract][Full Text] [Related]
9. Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease.
Lafargue MC; Bobot M; Rennke HG; Essig M; Carre M; Mercadal L; Farhi J; Sakhi H; Comont T; Golbin L; Isnard P; Chemouny J; Cambier N; Laribi K; Selamet U; Riella LV; Fain O; Adès L; Fenaux P; Cohen C; Mekinian A;
Kidney Int Rep; 2023 Dec; 8(12):2733-2741. PubMed ID: 38106568
[TBL] [Abstract][Full Text] [Related]
10. Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes.
Merz AMA; Sébert M; Sonntag J; Kubasch AS; Platzbecker U; Adès L
Cancer Treat Rev; 2024 Feb; 123():102673. PubMed ID: 38176221
[TBL] [Abstract][Full Text] [Related]
11. A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia.
Wang YH; Yao CY; Lin CC; Gurashi K; Amaral FMR; Bossenbroek H; Jerez A; Somervaille TCP; Binder M; Patnaik MM; Hou HA; Chou WC; Batta K; Wiseman DH; Tien HF
Br J Haematol; 2023 Apr; 201(2):302-307. PubMed ID: 36746431
[TBL] [Abstract][Full Text] [Related]
12. NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia.
Miller W; Holden J; George E; Stein K
Lancet Oncol; 2011 Apr; 12(4):326-7. PubMed ID: 21598446
[No Abstract] [Full Text] [Related]
13. Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
Castaño-Díez S; Pomares H; Esteban D; Guijarro F; Jiménez-Vicente C; Zugasti I; Álamo JR; Mayayo VT; López-Guerra M; de la Fuente C; Charry P; Cortés-Bullich A; Bataller Á; Maluquer C; Colomer D; Rozman M; Arnan M; Xicoy B; Esteve J; Díaz-Beyá M
Br J Haematol; 2024 Mar; 204(3):892-897. PubMed ID: 38013238
[TBL] [Abstract][Full Text] [Related]
14. Chronic Myelomonocytic Leukemia Presenting With Polyserositis and Seropositivity for Rheumatoid Arthritis.
Kunnumpurath A; Desikan SP; McClain C; Desikan R
J Investig Med High Impact Case Rep; 2020; 8():2324709620966863. PubMed ID: 33084368
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of intermediate or high-risk CMML patients treated with hypomethylating agents combined with venetoclax: A single center experience.
Li C; Deng C; Wu P; Liu K; Huang X; Li M; Chen X; Geng S; Lai P; Weng J; Du X
Clin Transl Sci; 2024 Jan; 17(1):e13711. PubMed ID: 38129985
[TBL] [Abstract][Full Text] [Related]
16. Should oligomonocytic CMML be classified as an independent disease entity?
Zhao HG
Br J Haematol; 2024 Mar; 204(3):749-750. PubMed ID: 38066684
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML.
Calvo X; Nomdedeu M; Santacruz R; Martínez N; Costa D; Pereira A; Estrada N; Xicoy B; Esteve J; Nomdedeu B
Leuk Res; 2015 Jul; ():. PubMed ID: 26354683
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Montalban-Bravo G; Kanagal-Shamanna R; Li Z; Hammond D; Chien K; Rodriguez-Sevilla JJ; Sasaki K; Jabbour E; DiNardo C; Takahashi K; Short N; Issa GC; Pemmaraju N; Kadia T; Ravandi F; Daver N; Borthakur G; Loghavi S; Pierce S; Bueso-Ramos C; Kantarjian H; Garcia-Manero G
Br J Haematol; 2023 Nov; 203(4):581-592. PubMed ID: 37608562
[TBL] [Abstract][Full Text] [Related]
19. Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome.
Wiseman DH; Baker SM; Dongre AV; Gurashi K; Storer JA; Somervaille TC; Batta K
EBioMedicine; 2020 Aug; 58():102904. PubMed ID: 32763828
[TBL] [Abstract][Full Text] [Related]
20. Atypical chronic myeloid leukaemia: A case of an orphan disease-A multicenter report by the Polish Adult Leukemia Group.
Drozd-Sokołowska J; Mądry K; Waszczuk-Gajda A; Biecek P; Szwedyk P; Budziszewska K; Raźny M; Dutka M; Obara A; Wasilewska E; Lewandowski K; Piekarska A; Bober G; Krzemień H; Stella-Hołowiecka B; Kapelko-Słowik K; Sawicki W; Paszkowska-Kowalewska M; Machowicz R; Dwilewicz-Trojaczek J
Hematol Oncol; 2018 Mar; ():. PubMed ID: 29512182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
